预约演示
CIRM grants funds to Ossium Health for OSSM-007 development
2023-05-01
细胞疗法临床研究免疫疗法基因疗法
Micrographs of grades of skin graft-versus-host-disease. Credit: Sakhila Ghimire, Daniela Weber, Emily Mavin,Xiao nong Wang,Anne Mary Dickinson and Ernst Holler1 / commons.wikimedia.org.
The California Institute skin graft-versus-host-disease) has awarded $3.46m Clinical Stage Research Programme (CLIN1) grant to Ossium Health for advancing OSSM-007 development to treat steroid-refractory acute graft versus host disease (GVHD).
OSSM-007 is the interferon-gamma primed mesenchymal stem cell product of Ossium Health.
The California Institute of Regenerative Medicine (CIRM)acturing activities of the product.Ossium HealthOSSM-007steroid-refractory acute graft versus host disease (GVHD)
OSSM-007any inteinterferon-gammaclinical study activities by the end of this year.
Acute GVHD occurs following allogeneic hematopoietic stem cell transplants (HCT).
It is a reaction where immunocompetent donor cells (the graft) identify and attack the tissues of a recipient.
Acute GVHDto Ossium Health, nearly 30 to 60% allogeneic HCT recipients develop acute GVHD and approximately half of them will become refractory to systemic steroid therapy.
Ossium Health CEO and co-founder Kevin Caldwell said: “We’re thrilled to partner with CIRM and appreciate their ongoing commitment to advancing research in stem cell-based therapeutics.
“This grant wOssium Healthe Ossium’s development of OSSM-007 and is a crucial sacute GVHDs a powerful new treatment option for patients with GVHD.”
Ossium Healthses its deceased donor bone marrow banking platform for developing cell tCIRMpies.
In March this year, the US Food and Drug Administration (FDA) accepted Ossium Health’s Investigational New Drug (IND) application for OSSM-001 to treat refractory perianal fistulas in Crohn’s disease patients.
Cell & Gene Therapy coverage on Pharmaceuticorthopaedic traumauphaematologic diseasesorgan rejection
Editorial content is indepeFood and Drug Administration (FDA)ighest staOssium Healthrnalistic integrity. Topic sponsors are not involvOSSM-001e creationrefractory perianal fistulasCrohn’s disease
Free Whitepaper
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
By Cytiva Thematic
-->
By Cytiva Thematics case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。